Back to Search

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

Recruiting Phase 3 Interventional Study
Obesity or Overweight Cardiovascular Disease
More trials: Heart Disease clinical trials· Heart Disease trials in Alabama
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
2,500 (estimated)
Sponsor
Hoffmann-La Roche · Industry
Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Participants with BMI ≥ 27 kg/m² and established CVD * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Known history of Type 1 diabetes mellitus * Current or previous treatment with petrelintide or any other amylin …
Contacts

Reference Study ID Number: CC46446 https://forpatients.roche.com/No attachments to email below.

888-662-6728 (U.S. and Canada)

global-roche-genentech-trials@gene.com

CONTACT

Fastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

NCT ID: NCT07843472 Source: ClinicalTrials.gov